Alnylam to Webcast Virtual R&D Day

CAMBRIDGE, Mass. ~ Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will be hosting a virtual R&D Day event on Wednesday, December 13th at 8:30 am ET. The event will be webcasted on the Investors section of the Company's website,, and a replay will be available within 48 hours after the event.

Alnylam Pharmaceuticals is a biotechnology company that has been translating RNA interference (RNAi) into innovative medicines since its founding in 2002. The company has developed five commercial RNAi therapeutic products: ONPATTRO® (patisiran), AMVUTTRA® (vutrisiran), GIVLAARI® (givosiran), OXLUMO® (lumasiran), and Leqvio® (inclisiran). Alnylam also has a deep pipeline of investigational medicines, including multiple product candidates that are in late-stage development.

More on Boston Chron
The company is executing on its "Alnylam P5x25" strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance. Alnylam is headquartered in Cambridge, MA and for more information about their people, science and pipeline can be found at or by engaging with them on X (formerly Twitter) at @Alnylam, or on LinkedIn, Facebook, or Instagram.

Christine Regan Lindenboom serves as contact for investors and media inquiries while Josh Brodsky serves as contact for investor inquiries at +1-617-682-4340 and +1-617-551-8276 respectively.
Filed Under: Business

Show All News | Report Violation


Latest on Boston Chron